Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it more effective without increasing toxicity?

This week, we explore the intensification of chemotherapy in an effort to improve overall survival. The second topic involves the use of monoclonal antibodies and targeted therapy to enhance existing regimens. Josh also conducts his characteristic deep dive, examining the evolution and application of the monoclonal antibodies cetuximab and panitumumab over the past 15 years. He aims to answer the long-standing question: does one size fit all for colorectal cancers?

Studies discussed in this episode:

FOLFOXIRI

Beva/Cetux

FIRE-3 Trial

TAILOR Trial

Crystal

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.